Foshan Biours Biosciences, an OTC patch maker, lacked release testing, cleaning validation, and stability data, so FDA says its drugs are adulterated.
What happened
FDA reviewed records the company submitted after FDA's April 3, 2020 request under section 704(a)(4), not an inspection. The records showed the company released an OTC patch for the U.S. without adequate identity and strength testing, had no validated cleaning procedure for non-dedicated equipment, and lacked stability data covering the active ingredient. FDA placed the product on Import Alert 66-40 on October 22, 2020.
What FDA found
The company did not test each batch of its OTC patch for identity and strength of the active ingredient before release.
21 CFR 211.165(a)The company had no validated cleaning procedure for non-dedicated equipment used to make and package the OTC patch.
21 CFR 211.67(b)The company's stability data for the OTC patch did not test the active ingredient, so it did not show the drug remains stable through expiry.
21 CFR 211.166(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and plans for release testing, cleaning validation, and stability testing for all U.S.-imported drug products. FDA also strongly recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC patches from this manufacturer
- U.S. importers and distributors of its drug products
- contract manufacturers using non-dedicated equipment
This is a summary. Read the original letter on fda.gov.